It is well established that besides regulating bone and calcium homeostasis vitamin D is involved in a multitude of fundamental cellular processes, including the cell cycle, apoptosis and differentiation, as well as effects on carcinogenesis, immune function, autoimmune diseases and cardiovascular disorders. Since supraphysiological doses of 1,25(OH)2D3, that are necessary to obtain these non-classical effects, result in hypercalcemia, a huge variety of analogs were developed to minimize the calcemic side effects while preserving or augmenting the beneficial effects of 1,25(OH)2D3. The development of DNA microarray technologies has created the opportunity to investigate the effects of 1,25-dihydroxyvitamin D3 on the gene expression profile in various cell types. So, in this study, we aimed to examine changes in gene expression associated with the vitamin D3 and its analogs stimulation in THP-1 cells. THP-1 monocytic human cells were treated with 4 hour 100 nM 1,25-Dihydroxyvitamin D3, 100 nM Gemini or 100 nM TX527 and the gene expression were examined using Illumina HumanHT-12 V4.0 expression BeadChip. Limma based gene prioritization identified a set of 224 genes with adjusted p-values < 0.05 for 1,25-dihydroxyvitamin D3 versus ethanol (113 up- and 111 downregulated genes), a set of 742 genes - for Gemini versus ethanol (268 up- and 474 downregulated genes) and a set of 1166 genes - for TX527 versus ethanol (429 up- and 737 downregulated genes). Differences in gene expression between stimulations with vitamin D preparations were generally implicit and by further analysis of overlapping genes, using published data for THP-1 cells, 15 up- and 3 downregulated genes were selected as vitamin D key target genes. Most of these vitamin D-induced genes are related to immune system regulation. Overall picture of gene set enrichment analysis showed a very low number of significant results, however overlapping with vitamin D pathways and ChIP-Seq datasets was clearly evident.